BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29888659)

  • 1. [Paclitaxel containing chemotherapeutic regimens in first line and reintroduced palliative treatment of metastatic cervical cancer].
    Kullmann T; Sipőcz I; Agyemang-Prempeh K; Barna O; Pintér T
    Orv Hetil; 2018 Jun; 159(24):974-977. PubMed ID: 29888659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.
    Lorusso D; Petrelli F; Coinu A; Raspagliesi F; Barni S
    Gynecol Oncol; 2014 Apr; 133(1):117-23. PubMed ID: 24486604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
    Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
    J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
    Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
    Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.
    Tinker AV; Bhagat K; Swenerton KD; Hoskins PJ
    Gynecol Oncol; 2005 Jul; 98(1):54-8. PubMed ID: 15904950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
    Choi HJ; Paik ES; Choi CH; Kim TJ; Lee YY; Lee JW; Bae DS; Kim BG
    Int J Gynecol Cancer; 2018 Sep; 28(7):1333-1341. PubMed ID: 30045137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors from a randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and cisplatin in metastatic or recurrent cervical cancer: Japan Clinical Oncology Group (JCOG) trial: JCOG0505-S1.
    Nishio S; Kitagawa R; Shibata T; Yoshikawa H; Konishi I; Ushijima K; Kamura T
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):785-90. PubMed ID: 27553435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
    Mabuchi S; Morishige K; Fujita M; Tsutsui T; Sakata M; Enomoto T; Kimura T
    Gynecol Oncol; 2009 May; 113(2):200-4. PubMed ID: 19268342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
    Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
    Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.
    Secord AA; Havrilesky LJ; Carney ME; Soper JT; Clarke-Pearson DL; Rodriguez GC; Berchuck A
    Int J Clin Oncol; 2007 Feb; 12(1):31-6. PubMed ID: 17380438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged remission of recurrent cervical carcinoma following paclitaxel and carboplatin chemotherapy with paclitaxel maintenance chemotherapy.
    Micha JP; Sassoon AF; Wong H; Goldstein BH
    Anticancer Drugs; 2015 Aug; 26(7):793-6. PubMed ID: 25933247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin.
    Takano M; Kikuchi Y; Kita T; Goto T; Yoshikawa T; Kato M; Watanabe A; Sasaki N; Miyamoto M; Inoue H; Ohbayashi M
    Onkologie; 2009 Oct; 32(10):595-7. PubMed ID: 19816078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
    Moore KN; Herzog TJ; Lewin S; Giuntoli RL; Armstrong DK; Rocconi RP; Spannuth WA; Gold MA
    Gynecol Oncol; 2007 May; 105(2):299-303. PubMed ID: 17303230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
    Downs LS; Chura JC; Argenta PA; Judson PL; Ghebre R; Geller MA; Carson LF
    Gynecol Oncol; 2011 Feb; 120(2):265-9. PubMed ID: 21145100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes.
    Mabuchi S; Isohashi F; Yokoi T; Takemura M; Yoshino K; Shiki Y; Ito K; Enomoto T; Ogawa K; Kimura T
    Gynecol Oncol; 2016 May; 141(2):240-246. PubMed ID: 26883141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better?
    Moore KN; Rowland MR
    J Clin Oncol; 2015 Jul; 33(19):2125-8. PubMed ID: 25987695
    [No Abstract]   [Full Text] [Related]  

  • 18. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix--a phase II study.
    Piver MS; Ghamande SA; Eltabbakh GH; O'Neill-Coppola C
    Gynecol Oncol; 1999 Dec; 75(3):334-7. PubMed ID: 10600285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.